Related Experiment Video
Updated: Aug 7, 2026
An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Cancer-Type-Specific Risks of Retinal Vascular Occlusion: A Nationwide Population-Based Study
Myung Soo Chang1, Seung Won Lee2, Gahyun Kim2
1Department of Ophthalmology, Institute of Vision Research, College of Medicine, Yonsei University, Severance Hospital, Seoul, South Korea.
Objective:
To evaluate the incidence and risk of retinal artery occlusion (RAO) and retinal vein occlusion (RVO) in cancer survivors across anatomical cancer subgroups.
Design:
Retrospective, nationwide, population-based cohort study.
Participants:
A total of 462 185 individuals newly diagnosed with cancer in South Korea between 2011 and 2022.
Methods:
Incident cancer cases were identified from the Korean National Health Insurance Sharing Service database. Malignancies were classified into anatomical subgroups according to the International Classification of Diseases, 10th Revision. Patients with multiple primary cancers or prior RAO or RVO were excluded. Risks were evaluated using age- and sex-adjusted standardized incidence ratios (SIRs) compared with the general population and multivariable Cox and Fine-Gray models within the cancer cohort. Sensitivity analyses were performed.
Main Outcome Measures:
Incident RAO and RVO after cancer diagnosis.
Results:
During a mean follow-up of 7.3 years, 873 RAO and 6657 RVO cases were identified. The 5-year cumulative incidence was 0.13% (95% confidence interval [CI], 0.12-0.14) for RAO and 0.91% (95% CI, 0.88-0.94) for RVO. Compared with the general population, cancer survivors had increased risks of RAO (SIR, 1.27; 95% CI, 1.19-1.36; P < 0.001) and RVO (SIR, 1.15; 95% CI, 1.12-1.17; P < 0.001). Hematologic malignancies showed the highest RAO risk (SIR, 2.50; 95% CI, 1.80-3.38; P < 0.001; hazard ratio [HR], 1.92; 95% CI, 1.41-2.62; P = 0.001) and an increased RVO risk (SIR, 1.52; 95% CI, 1.33-1.73; P < 0.001; Cox HR, 1.33; 95% CI, 1.17-1.52; P < 0.001). Eye and adnexa cancers showed the highest RVO risk (SIR, 3.03; 95% CI, 1.56-5.29; P = 0.002; Fine-Gray HR, 2.47; 95% CI, 1.41-4.34; P = 0.002). Findings were consistent in sensitivity analyses.
Conclusions:
Cancer survivors have significantly increased risks of both RAO and RVO compared with the general population. Hematologic malignancies showed elevated risks for both outcomes, whereas eye and adnexa cancers were most strongly associated with RVO. Retinal vein occlusion may be a relevant complication warranting further study in cancer survivorship.
Financial Disclosure(S):
The authors have no proprietary or commercial interest in any materials discussed in this article.
Related Concept Videos
01:27Diabetic Retinopathy
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:59Cancer Prevention
Some...
02:59Cancer Prevention
Some...
01:25Glaucoma: Overview